B-CELL APLASIA AFTER
CD19 CAR-T THERAPY

CD19 CAR-T cells are engineered to target all CD19-positive cells — a category that includes malignant B-cells and every healthy B-cell in the body. This on-target, off-tumour effect is expected and, in fact, a functional marker that the therapy is active.

• On-Target Off-Tumour Effect

  CAR-T cells cannot distinguish cancerous B-cells from healthy ones — both express CD19. Once infused, they eliminate all CD19+ cells systemically, leaving the patient without circulating B-lymphocytes.

• A Functional Marker of Activity

  Persistent B-cell aplasia confirms ongoing CAR-T cell activity and surveillance. Loss of aplasia — i.e., B-cell recovery — indicates CAR-T exhaustion or depletion, which in ALL patients can precede relapse.

• How Long Does It Last?

  Aplasia duration varies widely. Median persistence is 6–12 months in clinical trials, but some patients remain aplastic for 2–3 years. Longer aplasia is generally associated with durable remission.

• B-Cell Recovery and Relapse Risk

  In B-ALL patients, B-cell recovery on flow cytometry is a monitored relapse signal. Teams in China and India perform monthly peripheral blood flow panels post-infusion specifically to detect this.

Without functioning B-cells, the body cannot produce new immunoglobulins (antibodies). IgG levels fall progressively after CAR-T and, below 400 mg/dL, the patient becomes highly vulnerable to encapsulated bacterial infections and reactivation of latent viruses.

• Encapsulated Bacteria

  Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis rely on antibody opsonisation for clearance. Aplastic patients are at elevated risk of pneumonia, bacteraemia, and meningitis from these organisms.

• Viral Reactivation

  EBV, CMV, and VZV reactivation are monitored closely in the first 6–12 months. Monthly viral PCR panels are standard at major CAR-T centres in Beijing and Shanghai.

IVIG supplementation maintains serum IgG above the protective threshold while the patient's immune system is unable to produce its own. Dosing is weight-based and interval-driven.

1. 1

   Confirm IgG Level

   Measure serum IgG (quantitative immunoglobulins) at discharge and every 3–4 weeks thereafter. IVIG infusion is indicated when IgG falls below 500 mg/dL.

2. 2

   Calculate IVIG Dose

   Standard dose is 400–500 mg/kg IV per infusion cycle. For a 60 kg adult, this is 24–30 g per infusion. Adjust upward if IgG remains below 500 mg/dL at trough.

3. 3

   Infusion Frequency

   Administer every 3–4 weeks. Shorter intervals (every 3 weeks) are used when IgG troughs fall below 400 mg/dL or the patient has active infections.

4. 4

   Target IgG Trough

   Maintain IgG consistently above 500 mg/dL. Some centres target ≥700 mg/dL in paediatric patients and those with recurrent infections.

5. 5

   Monitor and Adjust

   Review IgG trough before each infusion. Reduce frequency when B-cell recovery is confirmed on flow cytometry and endogenous IgG production resumes.

Reference values from published CAR-T trials and clinical practice guidelines for B-cell aplasia management.

• 6–12 moMedian Aplasia DurationMedian persistence of B-cell aplasia following CD19 CAR-T infusion across major trials.
• 500 mg/dLIVIG Target IgGMinimum serum IgG trough to maintain protective humoral immunity during aplasia.
• 400–500 mg/kgIVIG DoseStandard weight-based IVIG dose per infusion cycle, administered every 3–4 weeks.
• +6 monthsVaccine DeferralLive vaccines must be deferred until B-cell recovery is confirmed plus an additional 6 months.

Most patients receive CAR-T in China and return to their home country within 8–12 weeks of infusion. Coordinating ongoing IVIG, monitoring, and infection management with a home-country physician who may be unfamiliar with CAR-T protocols is one of the most common challenges CancerFax helps solve.

“The discharge summary from your China hospital is not enough — your home physician needs a structured protocol they can actually act on.”

• What to Provide Your Home Doctor

  A translated discharge summary, a structured IVIG protocol (dose, interval, IgG target), a monitoring schedule (IgG trough, flow cytometry, viral PCR), and direct contact for the treating team in China.

• Vaccination Timing

  All live vaccines (MMR, varicella, yellow fever, live influenza) must be deferred until B-cell recovery is confirmed by flow cytometry plus a minimum of 6 additional months. Inactivated vaccines (influenza, pneumococcal, COVID-19) can be considered earlier but may generate poor responses during aplasia.

• Infection Red Flags

  Fever above 38°C, rigors, headache with neck stiffness, or respiratory symptoms in an aplastic patient require emergency evaluation — not watchful waiting. Alert your ER that the patient is functionally immunocompromised post-CAR-T.

• Coordination Support

  CancerFax prepares bilingual discharge protocol summaries, liaises between the China/India treating team and the home-country physician, and remains reachable for clinical queries during the post-infusion monitoring period.

Continue exploring the complete CAR-T treatment guide — from the main overview to related clinical topics.

Frequently Asked Questions

Common questions from patients and families managing B-cell aplasia after CAR-T therapy.